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One of the two main causes of acetylcholine-receptor loss in myasthenia gravis is antigenic modulation, 
i.e. accelerated internalization and degradation rate by antibody-crosslinking. This phenomenon has been 
studied only in animal tissues. Therefore, we tested antigenic modulation of the a~tylcho~ne receptor on 
human embryonic myotubes in culture. Several monocional antibodies to the a, @ and y subunits of the 
receptor educed its concentration, in some cases down to one-third of the control. Some of these antibodies 
only form complexes of one antibody with two receptor molecules; consequently such small complexes are 
sufficient o accelerate internalization of the human acetylcholine receptor. This technique might be proved 
valuable for clinical screening of sera from myasthenic patients. 
A~ety~cho~~ receptor Antigeni~ mod~atio~ ~onocio~~ ant~ody {bin myot~e j
Antib~y spec$city 
1. INTRODUCTION 
Nicotinic acetylcholine receptor is composed of 
5 subunits (~yz, @, y, 8) with a totaI’molecular mass 
of -250000. The 2 cy subunits carry the 
acetylcholine binding sites which regulate the 
opening of the cation channel (reviewed in [l]). 
Myasthe~a gravis is characterized by muscular 
weakness and fatigability largely due to 
autoantibody-mediated loss of AChR [2-51. 
Direct blockage of AChR function by the an- 
tibodies probably also contributes to the disease 
[6-81. Purified AChR or anti-AChR antibodies in- 
jected into animals cause experimental autoim- 
mune myasthena gravis [2-$91. Two-thirds of the 
Abbreviations: AChR, nicotinic acetylcholine receptor; 
MIR, main immunogenic region; mAb, monoclonal an- 
tibody; “%toxin, ‘251-labeled ~-bung~otoxin; fusion 
medium, Dulbecco’s modified Eagles medium plus 4% 
heat-inactivated normal human serum 
Receptor ~te~alization 
anti-AChR antibodies in immunized rats and 
myasthemc patients bind to the main immunoge~c 
region which is located on the LY subunit of the 
receptor [5,10-131. mAbs to the MIR injected into 
rats cause experimental myasthenia ([5,10] and 
Tzartos and Lindstrom, in preparation). 
Antibody-mediated Ioss of AChR is caused (i) 
by complement-mediated destruction of the 
postsynaptic membrane and (ii) by antigenic 
modulation, i.e. accelerated internalization and 
subsequently a degradation rate due to crosslink- 
ing of the receptors by the antibodies [3,4]. 
Myasthenic patients’ sera 17,151, immune animal 
sera [14] and mAbs [5,9,16,17] have been shown to 
cause antigen& modulation of AChR in animal cell 
and organ cultures. Among the tested mAbs of 
known region specificity only the anti-MIR ones 
caused antigenic modulation of animal AChR 
[ 16,171. AnimaI tissues used to evaluate the poten- 
cies of myasthenic patients’ sera present he serious 
disadvantage of testing only the crossreactive with 
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the human AChR antibody fraction [18]. 
Therefore use of human muscle cell cultures was 
needed. 
Here we report a net decrease in the overall 
AChR content after binding of mAbs to the MIR 
as well as to other regions using established em- 
bryonic muscle cell lines. 
2. MATERIALS AND METHODS 
All mAbs were derived from rats immunized 
either with fish electric organ or mammalian mus- 
cle AChR or its SDS-denatured subunits 
[11,13,20]. mAb preparations were obtained from 
culture media concentrated and dialysed against 
fresh Dulbecco’s modified Eagle’s medium. 
2.2. Human muscle cells 
Embryonic human muscle cell cultures were 
established in principle according to [ 191. Cells 
were cultured in Waymouth’s medium sup- 
plemented with 20% fetal calf serum in 5% COZ. 
At subconfluency, they were split 1: 3 and/or to 
96well microtiter plates. All the experiments were 
performed in the microwells using cells of passage 
nos 10-17. When cells in microwells reached con- 
fluency their medium was substituted with 1OOpl 
fusion medium. Surface AChR was evaluated by 
incubation with 40 /cl fusion medium containing 
10 nM 1251-toxin of specific activity -100 ,&i/pg. 
2.3. ~e~uremen~ of the effect of mAbs on the 
overall AChR content and on its 
internalization rate 
After -48 h culture in fusion medium, this 
medium was replaced with 40~1 fresh fusion 
medium supplemented with varying amounts of 
mAbs. For each mAb con~ntration 4-6 wells 
were cultured at 37°C and 4-6 wells at 15’C. After 
19 h, 10~1 fusion medium containing 50 nM “‘I- 
toxin (plus 5 pM unlabeled toxin for estimation of 
the background) were added to each microwell and 
cultures m~nt~ned for an additional hour at the 
same temperature. In some experiments 20pglml 
cyclohexamide (Sigma) was added together with 
the mAbs; 12?-toxin was added after 6 h and in- 
cubated for an additional hour. Subsequently, the 
wells were washed 5 times and the cell-bound 
radioactivity was released by 0.5% SDS and 
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counted. Remaining surface AChRs were 
estimated by the equation: 
% rem~ning AChR = 
1oo x fraction of detected toxin sites at 37°C 
fraction of detected toxin sites at 15°C 
=100 x 
Acpm s 37(mAb)/Acpm. 37 
Acpm - 15(mAb)/Acpm -15 
where Acpm. 37(mAb) and Acpm+ 37 were the 
specific cell-bound radioactivity after incubation 
at 37OC with or without the mAb, respectively, 
whereas Acpm - lS(mAb) and Acpm e 15 were the 
corresponding values for incubation at 15°C. 
3. RESULTS 
3.1. Human embryonic AChR on myotube 
~~iures 
We first performed binding studies on the AChR 
of these cells and established conditions required in 
subsequent experiments. Significant amounts of 
‘251-toxin binding sites appeared after -24 h in fu- 
sion medium with the peak binding at day 3 
(-3.5 fmol toxin binding sites per cm’). When ex- 
cess toxin was removed, about 80% of bound 12’1- 
toxin was already dissociated in the medium within 
3 h of incubation. Therefore, myotubes were first 
incubated with the mAbs and subsequently with 
‘2sI-toxin. 
To evaluate the normal AChR internali~tion 
rate, in absence of mAb, the myotube cultures 
were incubated with cyclohexamide to block pro- 
tein synthesis [21]. Fig. 1 shows that concentrations 
of cyclohexamide in the range 5-lOOpg/ml 
blocked A&R synthesis and apparently did not 
affect its intern~ization rate. Thus half-life of this 
AChR was -8.5 h. 
3.2. mAbs directed against a! and y subunits 
affected the overall AChR content of the 
human myotube cell surface 
Properties of all mAbs tested are shown in table 
1. They all crossreact with soluble human AChR 
(except of control mAb 26) and bind to various 
sites and subunits. Fig.2 shows the effect of mAbs 
on the overall AChR content after incubation for 
20 h. Binding of anti-MIR mAb 35 to myotubes 
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Fig.1. Cyclohexamide blocks synthesis of AChR of 
human embryonic myotubes. 3-day-old myotubes were 
cultured with 5 (o), 20 (B) or 100 pg/ml (A) 
cyclohexamide at 37’C or with 20pg/ml at WC (0). 
Remaining ‘251-toxin binding sites were measured as 
described in section 2 and divided by those in parallel 
cultures with no antibiotic. 
decreased surface AChR content down to approx- 
imately one-third of the control. Interestingly, at 
high concentrations of mAb 35 most of its effect 
disappeared apparently because at high antibody 
excess it did not crosslink AChRs anymore, but 
formed only 2 mAb with 1 AChR molecule com- 
plexes [ 161. We have observed this effect previous- 
ly in animal cells, but to a much lesser degree 
[la, 171. The other 2 anti-MIR mAbs (192 and 203) 
also decreased the AChR content to a similar 
degree though their action was independent of in- 
put antibody concentration. Differences in the Ig 
subclass of these mAbs in their orientation on the 
AChR or in their affinity for the antigen might ex- 
plain their different behaviour. 
The effect of mAbs 74, 66 and 69 (fig.2) is 
especially interesting since it is the first time that 
mAbs to sites other than the MIR have been 
observed to cause antigenic modulation of AChR. 
mAb 66 only forms complexes of 1 mAb with 2 
AChR molecules [20] thus precluding the forma- 
tion of large complexes. This was expected since 
AChR has only one y subunit but suggests that 
crosslinking of only 2 AChR molecules by a 
bivalent antibody is sufficient to accelerate their 
internalization. mAb 69 is unique in that it af- 
fected the AChR in 2 ways: blocking its toxin sites 
(as revealed by incubation at 15°C: fig.2, dashed 
line) and causing decrease in actual receptor 
number (fig.2, solid line). None of the other mAbs 
significantly blocked toxin binding at 15°C (not 
shown). 
Several lines of evidence suggested that the ef- 
fect of the mAbs was indeed on AChR internaliza- 
tion rate and not on the viability of the myotubes. 
First, their morphology was not affected and 
myotube formation continued for at least 5 days 
after mAb treatment. Second, high excess of some 
mAbs was at most as efficient if not less than lower 
Table 1 
Characteristics of anti-AChR mAbs used (from [ 11,13,20]) 
mAb Subunit and 
region specificity 
Ig class Immunogen Crossreaction with Increase degradation 
source soluble human AChR of mouse AChRs 
35 
192 
203 
66 
69 
73 
74 
64 
124 
137 
148 
26 
25 
(Y, MIR 
MIR 
(Y, MIR 
y, near MIR 
N.D. 
8, near MIR 
not near MIR 
8, cytoaphismic 
y, cytoplasmic 
B 
near MIR 
IgGl Electroph. 
IgG2b Human 
IgG2a Human 
IgG2a Calf 
IgG2a Calf 
IgGl Calf 
IgGl Calf 
IgG2a Calf 
IgGl Torpedo 
IgM Torpedo 
N.D. Torpedo 
IgG2a Electroph. 
IgG2b Electroph. 
+++ 
+++ 
+++ 
++ 
+ 
++ 
i- 
++ 
++ 
+ 
+++ 
Yes 
Yes 
Yes 
? 
? 
Slightly 
? 
No 
No 
? 
? 
No 
No 
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Fig.2. Effect of mAbs on the overall AChR content of 
human embryonic myotube surface. Incubation with the 
mAbs was at 37°C for 20 h. Inh~b~t~on f toxin binding 
to existing sites by steric hindrance was measured in 
parallel cultures at 15°C. This was 5 10% for all mAbs 
(not shown) except for mAb 69 (dashed line). Blocking 
of toxin binding was taken into account for calculation 
of the real AChR content at 37°C (see section 2). Most 
points are mean numbers of 2 or 3 independent expts 
with SD Z$ 12%. mAb concentrations were based on 
their apparent iter for the immunogen. Numbers denote 
mAb code numbers. 
concentrations. Finally, in protein synthesis ex- 
periments with [3~~~~~~~i~ni~e mAb-treated and 
untreated myotubes synthesized similar amounts 
of total protein (not shown). 
3.3. mAbs directed against a;fi and y subunits 
acceternted ~ntern~iiz~ti~~ of ACM 
We then tested separately the effect of mAbs on 
internalization of preexisting surface AChRs; syn- 
thesis of new AChRs was prevented by blocking 
protein synthesis with cyclohexamide. Fig.3 shows 
the increased internalization of AChRs after in- 
cubation with different mAbs for 7 h. The effect 
of most mAbs could be correlated with their effect 
on overall AChR content demonstrated in fig.2. 
However, anti-@ mAb 73, which slightly affected 
the net content of AChRs in the absence of 
cyclohexamide (fig.2) was found to increase the in- 
ternalization rate of AChR very efficiently (fig.3). 
This mAb also caused very little antigenic modula- 
tion of mouse AChR despite sufficient binding 
[ 171. These differences could be due to the absence 
of newly inserted AChRs in presence of cyclohex- 
amide in fig.3. In cases where antibody-binding af- 
finity is low, it is possible that transient crossfink- 
mAb InMi 
Rg.3. Effect of mAbs on the internalization rate of 
AChR by bIocking synthesis with 20pg/ml 
cydohexamide. Incubation was for 7 h at 37°C. At 15°C 
mAbs exhibited zz 10%~ inhibition of toxin binding (not 
shown). Most points are mean numbers of 2 expts. 
ing of 2 pre-existing AChR molecules might be 
more likely to allow their inter~aiization than 
when 1 of the 2 receptors has been synthesized e 
nova. Furthermore, the decrease in the total 
number of AChRs, brought about by blocked syn- 
thesis, might facilitate antigenic modulation. In 
fact, when tested at low concentrations, most 
mAbs were more effective in causing loss of 
AChRs under conditions where protein synthesis 
was blocked (fig.3). Whatever the explanation, it is 
interesting that an antibody directed towards the ,8 
subunit is sufficient to cause antigenic modulation 
of AChR. 
4. DISCUSSIQN 
Human muscle cell cultures producing sufficient 
amounts of AChR were needed to investigate the 
role of human anti-AChR antibodies on AChR an- 
tiger& modulation. Such cultures were established 
and as a first step we identified their AChRs and 
studied the effect of binding of different mAbs to 
these receptors, mAbs against the cy, P and y 
subunits of AChR accelerated internalization of 
the receptor and reduced its overall surface content 
to an extent comparable to that observed in 
myasthenic patients and experimental animaIs 
[3,4]. A single antibody (mAb 69) exerted a dual 
function: it accelerated AChR internalization as 
well as partially blocked toxin binding to remain- 
ing receptors. 
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Until now it was not known whether the forma- 
tion of large antibody-AChR complexes was re- 
quired or simple crosslinking of 2 AChR molecules 
by a bivalent antibody sufficient to induce AChR 
internalization. Addition of single IgG mAbs 
directed to unique epitopes on the P or y subunit 
should be unable to form.complexes larger than 2 
AChRs to I antibody molecule. Indeed sucrose- 
gradient-centrifugation experiments of mixtures 
containing anti-y mAb 66 and solubilized bovine 
AChR showed that only such small complexes 
couid be formed [20], whereas anti-MIR mAbs 
formed larger complexes as well [16,20]. 
Therefore, our observation that anti-y mAb 66 and 
anti-0 mAb 73 caused AChR loss suggests that 
such small complexes are also effective though 
with reduced efficiency. 
Because toxin binding to the studied human 
AChR was reversible, toxin was added after in- 
cubation with the mAbs in order to measure the re- 
maining surface AChRs. This technique gives 
greater experimental variation than prelabeling the 
AChRs with toxin but has the advantage of allow- 
ing the study of decrease in the overall surface 
AChR content of the myotubes as the result of 
both increased internalization and normal [3] if 
not increased [22] synthesis. Increased internaliza- 
tion was also tested independently of receptor syn- 
thesis by blocking its synthesis with cyclohexamide 
(fig.3). Using the established methods and cell 
cultures we are now testing sera from myasthenia 
gravis patients of different disease status, in an at- 
tempt to correlate their symptoms with the ability 
of their serum antibodies to mediate the loss of 
AChR. 
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